Company: Resverlogix Corp
Job title: Co-Founder and CSO
Dr. Wong is an endocrinologist with a clinical interest to reduce CVD risks in patients with T2DM. His previous studies in the area of chromatin structure enabled him to explore the potential benefits of an epigenetic therapy in lowering CVD risks. This novel therapy is an orally active compound Apabetalone that is a selective inhibitor of the second bromodomain (BD2) of bromodomain extraterminal proteins.
Selective Bromodomain Inhibition with the Bromodomain and Extraterminal Domain Inhibitor Apabetalone: Discovery to Phase 3 Cardiovascular Outcomes Study 3:15 pm
Epigenetic regulation and BET system in CVD/T2DM Mechanism of Apabetalone Highlights of Pre-clinical and Clinical DataRead more
day: Virtual Conference Day